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ABSTRACT
Aging with HIV poses unique and complex challenges, including avoidance of neurocognitive disorder. Our
objective here is to identify the prevalence and predictors of successful cognitive aging (SCA) in a sample of
older adults with HIV. One hundred three HIV-infected individuals aged 50 and older were recruited from the
Modena HIV Metabolic Clinic in Italy. Participants were treated with combination antiretroviral therapy for at
least 1 year and had suppressed plasma HIV viral load. SCA was defined as the absence of neurocognitive
impairment (as defined by deficits in tasks of episodic learning, information processing speed, executive
function, and motor skills) depression, and functional impairment (instrumental activities of daily living). In
cross-sectional analyses, odds of SCA were assessed in relation to HIV-related clinical data, HIV-Associated
Non-AIDS (HANA) conditions, multimorbidity (‡2HANA conditions), and frailty. A frailty index was cal-
culated as the number of deficits present out of 37 health variables. SCA was identified in 38.8% of participants.
Despite no differences in average chronologic age between groups, SCA participants had significantly fewer
HANA conditions, a lower frailty index, and were less likely to have hypertension. In addition, hypertension
(odds ratio [OR] = 0.40, p = .04), multimorbidity (OR = 0.35, p = .05), and frailty (OR = 0.64, p = .04) were
significantly associated with odds of SCA. Frailty is associated with the likelihood of SCA in people living with
HIV. This defines an opportunity to apply knowledge from geriatric population research to people aging with
HIV to better appreciate the complexity of their health status.
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Introduction
Due to the success of combined antiretroviral therapies(cART), many individuals with HIV can expect to live
longer lives and the population of people aged 50 and older
with HIV is growing.1 Despite increased longevity, people
aging with HIV appear to be at greater risk for poor health
outcomes compared with their uninfected peers, includ-
ing HIV-associated non-AIDS (HANA) conditions such
as cancer, cardiovascular disease, liver disease, and osteo-
porosis.1,3–5 People aging with HIV also appear to be at ex-
cess risk for neurocognitive impairment, a phenomenon that
has been termed HIV-associated neurocognitive disorders
(HAND).6–8
Compared with people of the same age without HIV,
people living with HIV also appear to exhibit greater severity
of frailty.9,10 Frailty is a state of increased vulnerability to
adverse outcomes, commonly seen in older adults.11 People
aging with HIV appear to exhibit vulnerability across mul-
tiple physiologic systems, evidenced by HANA conditions.
Frailty has been proposed as a useful marker of overall bio-
logical health and aging in this context, especially among
people with immune recovery and suppressed viral loads.9,12
As frailty is a holistic measure of health, it might be able to
more sensitively discriminate risk among people aging with
HIV than individual disease markers or comorbidity diag-
noses.12 Although early cross-sectional data have associated
frailty with vulnerability for multimorbidity and mortality
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among people with HIV,13 the relationship between frailty
and cognitive aging has not yet been established.
The absence of cognitive impairment can be considered a
measure of successful cognitive aging (SCA) and an impor-
tant clinical outcome among older adults with HIV. SCA has
been defined as aging without any subjective or objective
cognitive impairment, depressive symptoms, or functional
impairment.14,15 SCA prevalence estimates range between
19%14 and 32%15 among middle-aged and older adults with
HIV. Among people aging with HIV, SCA is associated with
better mental quality of life,14 medication adherence, and
capacity to interact with health professionals.15 However,
predictors of SCA are unknown, with one cross-sectional
study identifying no relationship between odds of SCA and
individual markers of HIV-disease severity, including current
CD4 cell count and HIV RNA viral load, or with individual
comorbidities, including diabetes or dyslipidemia.15
The objectives for the present study were to assess the
prevalence of SCA in a cohort of people with HIV aged 50
years and older and to identify health factors associated with
odds of SCA in this cohort, including whether SCA is asso-




Participants were recruited from the Modena HIV Meta-
bolic Clinic (MHMC) between July 1st and December 31st,
2013. The multidisciplinary MHMC, at the University of
Modena and Reggio Emilia, Italy, was initiated in 2004 to
assess metabolic changes among people with HIV and has
been described elsewhere.16 The current study is a cross-
sectional secondary analysis of existing data; criteria for in-
clusion in the present study were HIV-infected individuals
aged 50 years or older, on cART for at least 1 year, with
suppressed HIV viral load (<40copies/mL). Criteria for ex-
clusion were inability to speak Italian fluently and the pres-
ence of acute psychotic disorders or severe neurological
disease. All procedures followed were in accordance with the
ethical standards of comitato Etico provinciale di Modena
and with the Helsinki Declaration of 1975, as revised in 2000.
Successful cognitive aging
SCA was defined by the absence of depressive symptoms,
cognitive impairment, and functional impairment.15,17 As-
sessments of these domains are described next.
Depressive symptoms assessment
Depressive symptoms were assessed by using the 20-item
self-report Centre for Epidemiologic Studies Depression
scale. Items ask how often in the past week the participant has
experienced depressive symptoms, such as restless sleep,
feelings of loneliness, and poor appetite. Higher scores on
this measure indicate greater depressive symptoms; it is not
focused on somatic symptoms that could overlap between
depression and HIV infection itself.18 It has been validated in
many cohorts, including people living with HIV.18,19 Parti-
cipants with a score of 16 or above were identified as not
achieving SCA; scores above this cut-point indicate the
presence of many depressive symptoms and are found at a
much higher rate in depressed populations than the general
population.20
Neurocognitive assessment
Neurocognitive functioning was assessed with the Italian
version (cultural translation) of a validated abbreviated
neuropsychological battery.21 The battery took *25 min and
was designed to assess the cognitive domains most frequently
impacted by HIV-associated neurocognitive disorders, in-
cluding episodic learning (Rey Auditory Verbal Learning
test), information processing speed (Trail Making Test part
A), executive functions (Trail Making Test part B), and
motor skills (Non-Dominant grooved pegboard test).14 Cut-
points were age- and education specific and based on Italian
normative data.22 Impairment was defined as at least one
deficit in the following:
 Rey Auditory Verbal Learning Test (<28 was consid-
ered a deficit and, thus, did not meet criteria for SCA),
 Non-Dominant Grooved Pegboard Test (1 standard
deviation [SD] above the age-specific mean was con-
sidered a deficit and, thus, did not meet criteria for
SCA), and the
 Trail Making Test parts A (‡94 was considered a
deficit and, thus, did not meet criteria for SCA) and B
(‡282 was considered a deficit and, thus, did not meet
criteria for SCA).23–25
Functional assessment
Function was assessed with the Lawton-Brody Instru-
mental Activities of Daily Living (IADL) scale.26 Current
difficulty in one or more of the eight domains was considered
a functional impairment. IADL impairment was used, as it
was considered to be a more sensitive measure than impair-
ment in basic ADLs in this relatively young sample.27
HANA conditions
Current and nadir CD4+ T-cell lymphocyte counts were
categorized into clinically relevant groups as follows: >500,
351–500, 101–350, £100. Eight HANA conditions were ex-
amined: cardiovascular disease, end-stage kidney disease,
cancer, osteoporosis, hypertension, type 2 diabetes mellitus,
liver cirrhosis, and chronic obstructive pulmonary disease.
Cardiovascular disease was identified by clinical diagnosis
with history of myocardial infarction, stroke, revasculariza-
tion, or peripheral artery disease. End-stage kidney disease
was clinically diagnosed with estimated glomerular filtration
rate <60 mL/min as measured with Modification of Diet in
Renal Disease [MDRD] study equation.28 Cancer was iden-
tified as clinical diagnosis with biopsy confirmation. Osteo-
porosis was defined by dual-energy x-ray absorptiometry
T- or Z-score less than -2.5 or history of fragility fracture.
Hypertension was identified by clinical diagnosis with blood
pressure measured twice ‡140 systolic or ‡90 disatolic
mmHg or taking antihypertensive medicine. Type 2 diabetes
mellitus was defined as clinical diagnosis with measured
fasting glucose ‡126 or oral glucose tolerance test >200 or on
treatment. Liver cirrhosis was defined by FIB-4 score
>3.25.29 Chronic obstructive pulmonary disease was defined
by FEV1/FVC ratio <0.7. Multimorbidity was defined as the
presence of two or more of these conditions.
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Frailty index
A frailty index was calculated based on the established
deficit accumulation approach that has been described in
depth elsewhere.30 Briefly, the frailty index quantifies overall
physiologic vulnerability of an individual or organism.9,31,32
This model has shown that the combination of many different
health deficits can produce larger system effects, even if none
of the individual deficits are predictive in isolation. The
frailty index approach has been previously applied, and its
validity has been assessed in HIV-infected cohorts.13 Based
on current criteria, variables included in the frailty index
should number at least 30, be age related, and be associated
with adverse health, and as a group represent multiple
physiologic systems.30 The frailty index that we constructed
here included 37 variables that span multiple systems. First,
each variable was coded as 1, indicating a health deficit or 0,
indicating no deficit. The index score was then calculated as
the proportion of deficits present out of the total number of
variables considered31; this means that each individual in the
sample had a calculated frailty index score between 0 and 1,
representing the number of health problems they experience
and in effect, quantifying their health state. To assess the
effect of frailty independently from variables that are related
to HIV (markers of infection or immune function) or HANA
conditions, we did not include these variables as items in the
frailty index (see Supplementary Table S1; Supplementary
Data are available online at www.liebertpub.com/aid for list
of variables included). Further, we excluded variables from
the frailty index if they comprised the outcome (SCA), that is,
any cognitive, functional, or psychiatric variables.
Statistical analysis
Descriptive statistics were used to characterize the sample.
Individual logistic regression models were used to examine
the relationship between each of the current and nadir CD4
count, individual HANA conditions, multimorbidity, and
frailty with SCA as the primary outcome. All regression
models were adjusted for age and sex.
For each variable that was significantly associated with
SCA based on regression models, we tested its ability to
discriminate likelihood of SCA with receiver-operating
characteristic curves and evaluated the area under the curve
(AUC). Given the inverse relationship between SCA and the
explanatory variables, for ease of interpretation we used
‘‘unsuccessful cognitive aging’’ (those participants who did
not achieve SCA = 1-SCA) as the outcome, which is the same
binary variable but it allows us to look at positive relation-
ships with covariates (i.e., the presence of a condition, mul-
timorbidity, or frailty) and allows for a more straightforward
interpretation of AUC statistics.
All analyses were conducted by using SPSS (version 21.0,
SPSS, Inc.). All reported confidence intervals were 95%, and
statistical significance was set at a p value of .05.
Results
A total of 103 participants were included in our analyses
after giving informed consent. The mean age of the sample at
baseline was 56.4 years (SD = 6.1; range 50–81) (Table 1).
No participants were identified as having functional impair-
ment on self-report scales of IADL. The mean number of
HANA conditions for all participants was 1.2 (SD = 1.0), and
33% of participants had multimorbidity. The mean frailty
index was 0.26 (SD = 0.10), corresponding to 9.6 deficits of a
possible 37 deficits (Table 1). In total, 38.8% (n = 40) of
participants were identified as meeting criteria for research-
defined SCA. Despite no differences in average chronologic
age between groups, SCA participants had significantly fewer
HANA conditions, a lower frailty index, and were less likely
to have hypertension (Table 1).
Neither nadir nor current CD4 counts were significantly
associated with SCA in individual models adjusted for age
Table 1. Characteristics of the Study Sample (Modena HIV Metabolic Clinic)
Whole sample SCA Non-SCA
Sample size (n [%]) 103 [100] 40 [38.8] 63 [61.2]
Age (mean – SD) 56.4 – 6.1 57.0 – 6.7 56.0 – 5.7
Sex (female; n [%]) 28 [27.2] 13 [33] 15 [24]
Nadir CD4 (mean – SD) 178.9 – 141.3 179.7 – 129.7 178.1 – 149.2
Current CD4 (mean – SD) 611.0 – 212.9 604.2 – 171.1 615.4 – 237.3
Functional impairmenta 0 0 0
Number of HANAb conditions 1.2 – 1.0 0.9 – 1.0 1.3 – 1.0*
Frailty index (mean – SD) 0.26 – 0.10 0.23 – 0.09 0.28 – 0.10*
Multi-morbidity (n [%]) 34 [33.0] 9 [22.5] 25 [39.7]*
Successful cognitive aging (n [%]) 40 [38.8] — —
Cardiovascular disease (n [%]) 9 [8.7] 2 [5.0] 7 [11.1]
Hypertension (n [%]) 57 [55.3] 17 [42.5] 40 [63.5]*
Diabetes (type II; n [%]) 16 [15.5] 5 [12.5] 11 [17.5]
End-stage kidney failure (n [%]) 2 [1.9] 2 [5.0] 0
Liver cirrhosis (n [%]) 5 [4.9] 2 [5.0] 3 [4.8]
Chronic obstructive pulmonary disease (n [%]) 7 [6.8] 3 [7.5] 4 [6.3]
Osteoporosis (n [%]) 24 [23.3] 6 [15.0] 18 [28.6]
Cancer (any; n [%]) 1 [1.0] 0 1 [1.6]
aAs measured by difficulty with instrumental activities of daily living.
bHIV-Associated Non-AIDS.
*p < 0.05.
SCA, successful cognitive aging; SD, standard deviation.
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and sex ( p = .60, p = .45, respectively; Fig. 1). Hypertension
was the only HANA condition that was significantly associ-
ated with decreased odds for SCA (Fig. 1). Multimorbidity
was marginally statistically significant; specifically, the
presence of more than one HANA condition decreased the
odds of SCA by 65% [odds ratio (OR) 0.35, p = .05] (Fig. 1).
Frailty was significantly associated with SCA. Specifically,
for each 0.1 point increase in the frailty index, the odds of
SCA were reduced by 36% [OR 0.64, p = .04] (Fig. 1).
Receiver operating characteristic curves were employed to
assess the discriminative ability of factors found to be sta-
tistically associated with SCA in the individual logistic re-
gression analyses: hypertension, multimorbidity, and the
frailty index. The frailty index was the only variable found to
be statistically significant in its ability to discriminate the
SCA from those who did not meet criteria (AUC = 0.63,
p = .02). Hypertension and multimorbidity were not able to
discriminate the outcome in a statistically significant manner
( p = .08 and p = .14, respectively; Fig. 2).
Discussion
In this cross-sectional analysis of 103 people with aviremic
HIV aged 50 years and older, we found that frailty was in-
dependently, inversely associated with odds of SCA; whereas
CD4 counts, multimorbidity, and most individual HANA
conditions were not. Frailty, a comprehensive measure of
vulnerability, appears to be able to more sensitively dis-
criminate odds of SCA among people aging with HIV than
individual disease diagnoses or the presence of multi-
morbidity. Each additional health deficit decreased study
participants’ odds of meeting criteria for SCA by 12%, on
average (OR = 0.88, p = .04). This suggests that frailty might
have a meaningful impact on the ability to experience SCA in
people living with HIV.
Our findings are consistent with the few previous investi-
gations of SCA in individuals aging with HIV. The preva-
lence of SCA in our sample (38.8%) is similar to estimates
from previous studies of SCA that used similar criteria:
Average prevalence of SCA was 32% in a sample of
community-dwelling middle-aged and older adults,15 and
19% in a sample made up of young and older community-
dwelling adults living with HIV.14 These previous studies
also identified no relationship between SCA and markers of
HIV disease severity or comorbidities (including diabetes
and hypercholesterolemia).14,15 Although we found no sig-
nificant relationships between CD4 counts or comorbid
HANA conditions (besides hypertension) and odds of SCA,
frailty was significantly associated with odds of SCA. By
incorporating information across multiple physiologic sys-
tems, frailty might be describing important health informa-
tion over and above that of specific illnesses, demonstrating a
FIG. 1. Odds ratios and confi-
dence intervals based on separate
logistic regression models (adjusted
for age and sex) for each predic-
tor and its relationship to success-
ful cognitive aging (outcome).
*p < .05.
FIG. 2. Receiver operating characteristic curve for dis-
criminative ability of risk factors for successful cognitive
aging.
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potential role for assessing frailty in older HIV-positive
adults. Further, although the relationship between frailty and
SCA has not been previously assessed, a recent cross-
sectional study found a relationship between neurocognitive
impairment and the Veterans Aging Cohort Study (VACS;
another summary health measure) score among people aging
with HIV.33 Frailty, as measured by the frailty index, has also
been associated with dementia in the general population.34,35
Relationships between frailty and adverse health outcomes
are not yet well understood among people with HIV in the
cART era, although the few investigations of this relationship
produce consistent and compelling results that suggest that
frailty is useful in understanding the complexity of risk for
adverse health outcomes in those living with HIV.9,12 The 37-
item frailty index used in the current study was previously
found to independently predict survival and incident multi-
morbidity in the MHMC cohort.13 Further, a 31-item frailty
index predicted mortality and transitions in frailty severity.36
Frailty as measured with a five-item frailty phenotype was
predictive of mortality in a cohort of injection drug users,37
and frail individuals with HIV are also more likely to have
been hospitalized in the past year and to have longer hospital
stays.38 The VACS score has also been associated with ad-
verse health outcomes such as mortality39; greater severity of
frailty has been also been associated with higher VACS
scores.40 Frailty appears to be a promising approach to
measuring health status and vulnerability among people with
HIV, and larger, longitudinal studies of the relationship be-
tween frailty and cognitive outcomes are warranted.
Frailty has been described as physiologic vulnerability as a
consequence of reduced capacity to respond to stressors,
acknowledging that frailty is multifactorial and dynamic.41
The reduced capacity to respond to stressors is frequently
associated with increasing age, as there is more time with
which to accumulate deficits, but not everyone of the same
age experiences the same degree of frailty. This is a product
of multiple factors, including processes that are intrinsic to
the aging process itself and social and environmental expo-
sures that affect both the rate of insults and the body’s ability
to repair them.32 In people living with HIV, chronic inflam-
mation resulting from the virus, cumulative drug toxicity, and
excess rates of social and behavioral risk factors associated
with HIV disease may all contribute to frailty.9 For example,
frailty is associated with both current and nadir CD4 count,
but it appears to describe vulnerability independent from
these markers of HIV disease severity.13 As frailty is a phe-
nomenon that is not limited to one physiologic system, but
instead accounts for interaction and redundancy across
multiple systems, frailty might be valuable in describing the
complexity of multiple interacting health problems among
people aging with HIV.9,12
Rates of severe HIV-associated dementia have declined
substantially since the introduction of cART, but less severe
neurocognitive impairment still persists at high rates.6,7
Studies suggest that up to half of people living with HIV in
the United States might experience some form of cognitive
impairment despite cART,6 even with suppression of serum
HIV RNA viral load to undetectable levels.42 HAND in older
adults with HIV have been associated with both somatic and
psychiatric comorbidities2,6,7 as well as the VACS Index.33
Determination of predictors of SCA in HIV-positive indi-
viduals is a useful way to inform health promotion, manage
care in this population, and assist individuals in preserving
function, independence, and age successfully, despite their
HIV status. This study identifies the utility of the frailty index
in the prediction of SCA and proposes that a holistic approach
to physiologic vulnerability may be a useful approach to
capture the complexity of aging and HIV on cognition.
Our results should be interpreted with caution. Our analysis
was cross-sectional, and so temporal and causative relation-
ships cannot be established. In the future, we hope to extend
this to examine longitudinal data to understand what modi-
fiable factors might be predictive of SCA earlier in the life-
span. In addition, our sample size was relatively small and our
analysis will need to be replicated in larger cohorts to confirm
the generalizability of our findings and inform estimates of
SCA prevalence. Research on SCA among middle-aged and
older adults with HIV is limited, however, and our sample of
103 individuals aged 50 and older living with HIV compares
with previously published studies (n = 74 and n = 107),14,15
though it should be noted that our sample appears to be less
functionally impaired than other samples. Further compli-
cating our interpretation of the findings are other important
risk factors in people living with HIV, particularly chronic
inflammation, drug toxicity, and factors associated with the
virus itself that may all contribute to frailty. Further research
is needed to elucidate these mechanisms.
It is possible that these results are an under-representation
of the true potential of the frailty index; this is because our
analysis plan excluded any HIV-related or HANA condition
variables from inclusion in the frailty index. To test whether
including these variables would increase the ability of the
frailty index to predict adverse outcomes related to HIV, we
re-ran our analysis by using a comprehensive frailty index
including all variables (CD4 counts, HANA conditions) and
found that it had no more or less predictive ability than our
original frailty index. This is a phenomenon noted in other
investigations of the frailty index; specifically, it has been
demonstrated that the predictive ability of the frailty index is
optimized at the inclusion of 30 variables, after which pre-
dictive ability is not additive with additional variables.36 Our
rationale for leaving these variables out of the frailty index in
this article was to clearly demonstrate that the frailty index
captures a state of physiologic vulnerability that is indepen-
dent of these potentially disease-specific variables.
It is also important to consider whether blood pressure is a
‘‘good enough’’ proxy for health status, given these results.
Although blood pressure may be readily available, the ad-
vantage of the frailty index is that it can be operationalized by
using any and all routinely collected data. Further, the frailty
index has a much smaller confidence interval than hyperten-
sion (Fig. 1), leading us to believe that frailty may be a more
precise measure of health status, rather than just a proxy.
In summary, we found that frailty is associated with the
likelihood of SCA in people living with HIV. This defines an
opportunity to apply knowledge from geriatric population re-
search to people aging with HIV to better appreciate the
complexity of their health status. We hope that this will inform
future research on treatment, management, and health service
access for people aging with HIV and highlight the need to
consider how to best support these individuals in their unique
aging experience. Specific mechanisms by which frailty, HIV
infection, and cognition are related remain poorly understood,
and these are motivating future inquiry by our group.
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